William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.
Gentry King, MD, discusses an ongoing feasibility study on multiomic platform‑based testing in patients with localized and resectable biliary tract cancers.
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results…
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
Stay in the know.
OncNet Newsletter